+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Pharmacological characterization of dopaminergic influence on expression of neuropeptide Y immunoreactivity by rat striatal neurons



Pharmacological characterization of dopaminergic influence on expression of neuropeptide Y immunoreactivity by rat striatal neurons



Neuroscience 26(3): 809-817



Selective unilateral lesion of the nigrostriatal dopamine pathway by the cytotoxin 6-hydroxydopamine was previously shown to enhance the number and staining intensity of neurons expressing neuropeptide Y immunoreactivity in the ipsilateral striatum. This effect was completely reversed by treatment of the 6-hydroxydopamine-injected animals with the directly acting dopamine agonist apomorphine. This finding reinforces our previous hypothesis that changes in striatal neuropeptide Y staining subsequent to 6-hydroxydopamine lesions of this kind reflect changes in intraneuronal neuropeptide Y levels which are directly attributable to the suppression of a tonic dopaminergic control. In contrast to the effect of 6-hydroxydopamine lesion, non-destructive impairment of striatal dopamine transmission by treatments with either the dual dopamine D1/D2 receptor antagonist haloperidol or the dopamine synthesis inhibitor alpha-methylparatyrosine induced a decrease in both the number of neuropeptide Y striatal cells (-29.8% and -34.8%, respectively) and in their labeling intensity. The selective D2-antagonist sulpiride also showed a tendency to reduce the number of neuropeptide Y immunoreactive cells, whereas the selective D1 antagonist SCH 23390 induced a small but constant increase in this number. Taken as a whole, these results suggest that the dopaminergic D1 and D2 receptor subtypes play opposite roles in the dopaminergic control of the striatal neuropeptide Y neuronal system, which may account for the different changes in striatal neuropeptide Y immunostaining observed after 6-hydroxydopamine injury and after non-destructive impairment of nigrostriatal dopaminergic transmission.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 040960736

Download citation: RISBibTeXText

PMID: 3143926

DOI: 10.1016/0306-4522(88)90101-7


Related references

Striatal neuropeptide y neurons are under the influence of the nigrostriatal dopaminergic pathway immunohistochemical evidence. Neuroscience Letters 66(1): 106-112, 1986

An inhibitory dopaminergic regulation of the neuropeptide Y immunoreactivity expression in the rat cerebral cortex neurons. Neuroscience. 66(3): 589-595, 1995

Striatal neuropeptide neurons undergo tonic influence from nigrostriatal dopaminergic afferents immunohistochemical evidence. Neuroscience Letters Supplement: 607, 1986

Expression of neuropeptide Y immunoreactivity in the rat nucleus accumbens is under the influence of the dopaminergic mesencephalic pathway. Experimental Brain Research 81(2): 363-371, 1990

D-1 dopamine receptor agonist-induced fos-like immunoreactivity occurs in basal forebrain and mesopontine tegmentum cholinergic neurons and striatal neurons immunoreactive for neuropeptide Y. Neuroscience. 59(2): 375-387, 1994

Neuropeptide dopamine interactions iv. effect of trh on striatal dopaminergic neurons. Peptides (New York) 10(3): 681-686, 1989

Neuropeptide-dopamine interactions. IV. Effect of thyrotropin-releasing hormone on striatal dopaminergic neurons. Peptides 10(3): 681-685, 1989

Inhibitory influence of nigro striatal dopaminergic neurons on cortico striatal glutamatergic activity in the rat striatum. Neuroscience Letters (Suppl. 14): S261, 1983

Inhibitory influence of the mesocortical dopaminergic neurons on their target cells: electrophysiological and pharmacological characterization. Journal of Pharmacology and Experimental Therapeutics 258(2): 728-738, 1991

Host dopaminergic afferents affect the development of DARPP-32 immunoreactivity in transplanted embryonic striatal neurons. Neuroscience 48(4): 857-869, 1992

Acute and chronic amphetamine treatments differently regulate neuropeptide messenger RNA levels and Fos immunoreactivity in rat striatal neurons. Neuroscience. 65(4): 1041-1050, 1995

Pharmacological modulation of development and plasticity in nigro striatal dopaminergic neurons. Pharmacological Research 25(Suppl. 1): 29-30, 1992

Striatal neuropeptide Y neurones are under the influence of the nigrostriatal dopaminergic pathway: Immunohistochemical evidence. Neuroscience Letters 66(1): 106-112, 1986

Pharmacological characterization of the release of neuropeptide Y-like immunoreactivity from the rat hypothalamus. Neuropharmacology. 32(8): 819-825, 1993

Dopaminergic parameters and striatal neuropeptide expression in monkeys with different forms of MPTP-induced parkinsonism. Society for Neuroscience Abstracts 25(1-2): 1598, 1999